Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLU, ATNX and EBS

Thursday, 29 April 2021 10:25 AM

The Klein Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / April 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

BELLUS Health Inc. (NASDAQ:BLU)
Class Period: September 5, 2019 - July 5, 2020
Lead Plaintiff Deadline: May 17, 2021

Throughout the class period, BELLUS Health Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.

Learn about your recoverable losses in BLU: http://www.kleinstocklaw.com/pslra-1/bellus-health-inc-loss-submission-form?id=15298&from=1

Athenex, Inc. (NASDAQ:ATNX)
Class Period: August 7, 2019 - February 26, 2021
Lead Plaintiff Deadline: May 3, 2021

The ATNX lawsuit alleges Athenex, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ATNX: http://www.kleinstocklaw.com/pslra-1/athenex-inc-loss-submission-form?id=15298&from=1

Emergent Biosolutions Inc. (NYSE:EBS)
Class Period: July 6, 2020 - March 31, 2021
Lead Plaintiff Deadline: June 18, 2021

The complaint alleges Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EBS: http://www.kleinstocklaw.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?id=15298&from=1

The Klein Law Firm, Thursday, April 29, 2021, Press release picture

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: